In the midst of disaster -- and we can realistically say that stock market performance over the last few weeks has been nothing short of disastrous – many of us can retort, at the risk of sounding glib, “well, we at least have our health.”
So it is that among the few stocks not folding the tent, indeed, pointing upward is Houston-based AngioSoma (OTC:SOAN), a wellness company dedicated to "bringing innovative, effective and high-quality supplement products to the medical, wellness and adult-use markets."
The firm announced Monday what it calls an “innovative marketing strategy for its 15 newly-acquired intellectual properties.” Most of the properties focus on important unmet medical needs, both over the counter and pharmaceutical.
Not to stand pat, the company’s 16th new product included in the newly developed marketing plan is FULL SALUTE, a male ED (erectile dysfunction) product that contains E. brevicornum extract, an all-natural phosphorodiesterase-5 inhibitor (biosimilar to Cialas and Viagra).
Said AngioSoma President Alex Blankenship, "We are excited about the prospects for our fully developed marketing plan that follows finalizing the settlement agreement to conclude the two-year legal dispute between founder David Summers and AngioSoma. We believe our plan will move the new products into the market."
COAN shares roared ahead 40% to 14-100ths of a cent in Monday’s last hour, on 23.7 million shares.
North of the border, we also salute Vancouver-based Algernon Pharmaceuticals Inc. (CSE:AGN), which told investors Monday it’s set to start production of NP-120 (Ifenprodil) with a new injectable and long-acting oral release formulation, in order to be prepared for new U.S. clinical trials for COVID-19 (coronavirus) and acute lung injury (ALI).
The decision was made after a recent independent study found that Ifenprodil significantly reduced ALI and improved survivability in an animal study with Asian H5N1 infected mice by 40%. Asian H5N1 is the most lethal form of influenza known to date with an over 50% mortality rate.
